Glanzmann thrombasthenia (GT) is caused by inherited defects of the a IIb b 3 platelet glycoprotein. This bleeding disorder can be treated with platelet transfusion therapy, but some patients will be immunized and begin to form anti-human leucocyte antigen (HLA) and/or anti-a IIb b 3 antibodies. These antibodies can bind and interfere with the function of the transfused platelets, rendering treatment ineffective. However, platelet transfusion refractoriness attributable to HLA antibodies may be managed by the selection of compatible donors, although they are not always readily available, particularly in an emergency. Thus, anti-a IIb b 3 antibodies represent one of the most severe complications in GT. Both genetic and environmental factors may contribute to the risk of anti-a IIb b 3 development, but the underlying pathogenic mechanisms are still unknown. This review will summarize the current knowledge of the risk factors for development of anti-a IIb b 3 antibodies in patients with GT and discuss how these findings may influence the clinical management of patients.
Glanzmann thrombasthenia (GT) is a rare autosomal recessive bleeding disorder caused by inherited defects of the genes encoding the platelet a IIb b 3 integrin (Nurden, 2006; Nurden et al, 2011) . Once activated, this receptor binds many different extracellular matrix proteins, including fibrinogen and von Willebrand factor, allowing platelets to adhere to the sub-endothelium and to aggregate. Thus, this disease is characterized by a lack of platelet aggregation in response to all physiological stimuli, except ristocetin. GT has been classified into three subtypes. Types I and II show quantitative abnormalities, with a IIb b 3 either absent or present in trace amounts (<5%, type I) or at levels varying from 5% to 30% of those of normal donors (type II). Variant GT is characterised by qualitative abnormalities that prevent the function of a IIb b 3 , but allow its reduced or even normal surface expression in platelets.
The ITGA2B gene encodes for the a IIb subunit while the ITGB3 gene encodes for b 3 ; these two genes are closely located on chromosome 17q21 without evidence of coordinated expression . Mutations causing GT can affect either of these two genes. As GT is an autosomal recessive disease, patients are often compound heterozygotes in absence of consanguinity.
Generally, bleeding is largely mucocutaneous in nature and if minor, local measures, sometimes in conjunction with anti-fibrinolytics, are sufficient; in contrast, platelet transfusions are used to control or to prevent life-threatening blood loss (Poon et al, 2004; Bolton-Maggs et al, 2006; Di Minno et al, 2009) . Unfortunately, platelet transfusion therapy can trigger an immune response that is usually directed against a IIb b 3 and/or against major histocompatibility complex (MHC)-Class I molecules (Taaning et al, 1997; Martin et al, 2002; Flood et al, 2005; Santoro et al, 2010) . Such antibodies are produced when the immune system comes into contact with transfused donor platelets.
Anti-human leucocyte antigen (HLA) platelet antibodies can be managed by the use of HLA-compatible donors. Thus, presence of anti-a IIb b 3 antibodies is the most crucial problem for management of GT patients. Naturally occurring antia IIb b 3 antibodies may cause the removal of, or render ineffective, transfused donor platelets (Conte et al, 1997; Bellucci et al, 2000) . The management of pregnancy in immunized women is also a real challenge (Leticee et al, 2005) . One of the major complications relates to fetal immune thrombocytopenia induced by the transplacental passage of the maternal anti-a IIb b 3 antibodies, which can lead to severe haemorrhage and fetal loss (Leticee et al, 2005) .
Despite reports of anti-a IIb b 3 antibodies in GT patients, the aetiology of development remains unclear. The risks have been linked to genetic-or treatment-related variables, but there is still no consensus pertaining to predictive indicators to determine whether or not a GT patient will develop an immune response. In this review, we summarize current knowledge regarding the formation of anti-a IIb b 3 antibodies, as well as therapeutic management that could be employed to treat patients.
Anti-a IIb b 3 antibodies specificity and incidence Initial reports of platelet antibody formation in GT were largely isolated cases and mainly concerned a IIb b 3 antibody characterization. Previous detailed studies of these antibodies show that they recognize epitopes located on a IIb b 3 or b 3 and that some can block platelet function as well as cause platelet elimination (Degos et al, 1975; Coller et al, 1986; Bierling et al, 1988; Jallu et al, 1992 Jallu et al, , 1994 . A polytransfused thrombasthenic patient came to attention when an antibody directed against a IIb b 3 was detected in his serum and has been the subject of numerous published reports. This antibody bound strongly to a IIb b 3 and predominantly reacted with a IIb b 3 complex-dependent epitopes (Rosa et al, 1984) . It inhibited ADP-, epinephrine-, collagen-or thrombin-induced aggregation of normal human platelets, and fibrinogen-binding was proportionally blocked after addition of the purified antibody (Lee et al, 1981) . Also, it strongly inhibited clot retraction (Levy-Toledano et al, 1978) . Therefore, anti-a IIb b 3 antibodies may induce a thrombasthenia-like state in normal human platelets.
Monoclonal antibody-specific immobilization of platelet antigens (MAIPA) is still considered as the reference method for evaluating the presence of anti-a IIb b 3 antibodies in GT patients. Briefly, platelet-rich plasma (PRP) is obtained by centrifugation and platelets are washed before being resuspended (Clofent-Sanchez et al, 1996) . A volume of the platelet suspension is then sensitized with serum from the patient or control donors. After resuspension, selected platelet glycoprotein-specific monoclonal antibodies directed against a IIb b 3 , b 3 and/or a IIb subunits are added separately and the mixture is incubated at room temperature. Platelets are then washed and solubilized in a lysis solution by incubating overnight at 4°C. In parallel, microtitre plates are coated with antibodies directed against the specific monoclonal antibodies and incubated overnight at 4°C. After several washes, a blocking buffer and a volume of alkaline phosphataselabelled goat antihuman IgG/M F(ab'2) is added to each well. After incubation, the tray is washed and substrate (paranitrophenylphosphate in diethanolamine buffer) is added and absorbance measured in a microplate reader. Patients' results are calculated as a ratio of their optical density (OD) compared to that of the mean value of a series of control sera.
The use of Pak platelet antibody screening kit (Immucor, Norcross, Georgia, USA) has also been reported (Santoro et al, 2010) . The technique, which is much simpler than the MAIPA assay, is based on the incubation of test sera in platelet glycoprotein-coated microwells. After incubation, the cells are washed to remove unbound proteins, and any antibody bound to the microwell is detected using an alkalinephosphatase-conjugated antihuman globulin reagent and the appropriate substrate. Results are considered positive when the ratio of the mean OD of the test sample to that of the OD for normal control sera is ≥ 2.
While the epidemiology of neutralizing antibodies (inhibitors) is well known in patients with haemophilia (Hay et al, 2011) , it has been poorly studied in GT and the actual frequency of this complication remains unknown (Table I) . The first large case series reporting this complication dates back to 1990 where a very low frequency of 3Á5% (6/177) was observed (George et al, 1990) . Fourteen years later, an international survey was conducted in 59 GT patients, including 21/54 patients (39%) with current or previous antiplatelet antibodies (Poon et al, 2004) . More recently, Santoro et al (2010) investigated 16 GT patients for the presence of anti-platelet antibodies and showed that anti-a IIb b 3 antibodies were present in 2/16 patients (12Á5%). In 2012, we reported the results of an antibody screen on a series of 24 GT patients from South-West France, dividing them into two cohorts: (i) 16 patients with the French gypsy mutation (Fiore et al, 2012) . We showed that 81% (13/16) of the French Gypsy patients had developed platelet antibodies against a IIb b 3 . In contrast, only 25% (2/8) of the patients with other GT mutations were concerned. In 2015, a large international study on GT patients showed that 20/83 of them (24%) developed antibodies to a IIb b 3 (Nurden et al, 2015) and, in the largest international prospective registry of 218 GT patients, 47 (22%) had a history of anti-a IIb b 3 platelet antibodies (Poon et al, 2016) . Finally, the incidence of immunization in different studies varies considerably. In addition to patient-or treatmentrelated risk factors, diagnostic procedures (possibly due to the disappearance of antibodies at the time of the test or insufficient sensitivity of some assays) may influence the frequency of the observed events. Based on the two largest studies published so far (Nurden et al, 2015; Poon et al, 2016) , the estimated prevalence of this complication is probably comprised between 20-30%. However, among some ethnic minority groups, frequency may be much greater.
Related-risk factors
Genetic, as well as acquired patient-related factors are likely to influence the process of anti-a IIb b 3 immunization. Nevertheless, it remains poorly known whether patients can make antibodies or not when exposed to these risk factors. Although some parameters are considered as risk factors for inhibitor development in haemophilia, they have never been really evaluated in GT.
Gender-related risk factor
There is currently no scientific data establishing a causal link between gender and the risk of anti-a IIb b 3 formation. However, of the 20 patients with anti-a IIb b 3 antibodies reported in the recent international study (Nurden et al, 2015) , 14 were female and only six were male. This data suggests that female patients could develop anti-a IIb b 3 antibodies more easily than male patients. However, it is also possible that female patients are more exposed to platelet transfusions due to their bleeding challenge (menarche, pregnancy).
Ethnicity-related risk factor
In relation to their factor VIII background haplotypes, the prevalence of factor VIII inhibitors in black patients is about twice that in white patients (Viel et al, 2009 ). Many genetic polymorphisms within the sequenced regions of ITGA2B and ITGB3 generate different haplotypes (Pillois & Nurden, 2016) . The frequencies with which these polymorphisms exist in a population have been shown to be ethnically related. For example, we previously found that a haplotype of five polymorphic variants covering a 4-cM region was strongly associated with the French Gypsy mutation, suggesting a founder effect . Some of these ethnicityrelated polymorphisms could be associated with a higher risk of anti-a IIb b 3 development, but this has not yet been proved. Haplotypes characterization might be used as a basis for studies on the relationship between integrin genotypes and anti-a IIb b 3 antibodies formation. These results could determine whether mismatched replacement therapy is a risk factor for the development of anti-a IIb b 3 antibodies.
Risk factors associated with blood product transfusion
In view of the increased risk of bleeding associated with GT, platelet transfusion should be given before invasive procedures and sufficient platelet concentrates should be used to overcome this inherited platelet dysfunction (Bolton-Maggs et al, 2006) . Despite the lack of supporting scientific study, concentrates of apheresis platelets, HLA-compatible if needed, are still preferred (Bell & Savidge, 2003 , British Committee for Standards in Haematology 2003; New York State Council on Human Blood and Transfusion Services 2012). Regarding the correlation between transfusion intensity and immunization, it has been previously observed that some immunized patients had been heavily treated with platelet transfusions, while others had not received a very high number of platelet units (Santoro et al, 2010) . Moreover, some immunized patients might become positive after having received just a single platelet concentrate few days earlier (Fiore et al, 2012) . This confirms that it is not necessary to be highly exposed to normal platelets to develop antibodies against a IIb b 3 . Moreover, the time between platelet transfusion and antibody screening shows that platelet antibodies against a IIb b 3 may still be present after several years (Fiore et al, 2012) .
Moreover, red blood cells (RBC) administrations may also expose GT patients to the risk of anti-a IIb b 3 antibody development. This may presumably be due to stimulation of the immune system by the presence of residual platelets in RBC concentrates (George et al, 1990) . This hypothesis was confirmed by Laurian et al (2005) , who described the case of a 16-year-old girl with type I GT and a past history of antia IIb b 3 antibodies. When antibodies were no longer detectable, she received RBC concentrates for severe anaemia, and antibodies to a IIb b 3 were found a few weeks later. So, RBC transfusions may expose patients to the risk of anti-a IIb b 3 development or anamnestic rise and this could be avoided by the use of washed or frozen RBC, which removes virtually all platelets (Laurian et al, 2005) .
Genetic risk factors
Most of GT patients with immunization against a IIb b 3 are affected by type I disease (Nurden et al, 2015) . Anti-a IIb b 3 antibody formation has been rarely notified in type II or variant forms (Bellucci & Caen, 2002; Nurden et al, 2010) . Thus, the risk of immunization is largely restricted to patients whose platelets lack a IIb b 3 on their platelet surface (Nurden et al, 2015) .
The type of mutations affecting ITGA2B or ITGB3 genes could also influence the risk of developing antibodies. Molecular anomalies associated with GT fall into two groups: (i) those which are highly deleterious, leading to inhibition of protein synthesis (null mutations: non-sense or frameshift mutations, splicing defects introducing premature stop codons), where the risk of anti-a IIb b 3 immunization is probably very high; and (ii) those where a residual synthesis of the integrin may persist (missense mutations) with probably a lower risk of anti-a IIb b 3 antibodies development. Based on the literature data, most of the mutations known to be associated with anti-a IIb b 3 antibodies are homozygote or compound heterozygote for premature termination mutations (Kashiwagi et al, 2011) . Exceptions mostly concern homozygote patients for missense substitutions who may produce antibodies after massive platelet transfusions (Santoro et al, 2010) .
Although published data suggest that some mutations might increase the risk of antibody formation, further studies are required to confirm the importance of the causative gene mutation. Moreover, another point that remains elusive is the concordance rate for antibodies development between GT patients carrying the same mutation . Indeed, while some patients have the same mutation, the strength and persistence of antibodies over time varied between individuals, suggesting that other genetic factors (e.g. genes encoding MHCs, other gene polymorphisms) play key roles in the selection of antibody repertoires (Fiore et al, 2012) .
Environmental risk factors
It is still unknown whether GT patients who have not received platelet or RBC transfusions may develop anti-a IIb b 3 antibodies. Nurden et al (2015) reported an immunized woman from the French gypsy tribe who had not received platelet or RBC transfusions and the cause of her immunization remains unknown. Ghosh et al (2009) also observed this in a study of antiplatelet antibodies formation in 15 paediatric patients with GT who had not received transfusions. Surprisingly, all of them showed the presence of antiplatelet antibodies. They might be produced as a result of molecular homology to bacterial or viral components. Indeed, Chouhan et al (2011) identified bacterial sequences that are similar to the human integrin b-propeller domain. Nevertheless, whether antigenic mimicry to some bacterial or viral peptides, which are common in our environment, is the cause for this finding needs to be determined.
Pregnancy
Pregnancy should be closely monitored in woman affected by GT, particularly in case of anti-a IIb b 3 immunization.
Unfortunately, information is scarce on this matter. Siddiq et al (2011) previously reported an interesting systematic review of the management and outcomes of pregnancy in GT patients. This identified descriptions of 40 pregnancies in 35 women that resulted in 38 live births. Maternal antibodies showed specificity against a IIb b 3 in 9/22 (41%) documented pregnancies (Sundqvist et al, 1981; Pico et al, 1987; Vivier et al, 1989; Ito et al, 1991; Kiefel et al, 1992; Kashyap et al, 1997; Boval et al, 2001; Monrigal et al, 2003; Leticee et al, 2005) . Among these pregnancies, antibody-directed therapies were attempted in 3/9 (33%) [plasma exchange 2/9 (22%) (Vivier et al, 1989; Ito et al, 1991) ; corticosteroids 1/9 (11%) (Kashyap et al, 1997) ]. There were 2/9 (22%) in utero deaths arising from intracranial haemorrhage (Boval et al, 2001; Leticee et al, 2005) . Neonatal thrombocytopenia was reported in three cases (Sundqvist et al, 1981; Pico et al, 1987; Kiefel et al, 1992) , one of whom had a platelet count of 35 9 10 9 /l, associated with a cephalohaematoma and conjunctival haemorrhages (Kiefel et al, 1992) . Following infusion of intravenous immunoglobulins over 3 consecutive days, platelet counts rose to normal values. These data confirm that maternal anti-a IIb b 3 immunization may be associated with fetal thrombocytopenia and in utero death (see also Therapeutic Approach Section). In GT patients, anamnestic response with rise in antibodies against a IIb b 3 titre has been previously observed during pregnancy (Vivier et al, 1989; Monrigal et al, 2003) , suggesting that immunization may also be a consequence of exposure to fetal platelet antigens. In these cases, absence of platelet-specific antibodies at the start of pregnancy does not preclude their occurrence at a later date.
More recently, Wihadmadyatami et al (2016) described immunization against a v b 3 in a type I GT patient. Indeed, b 3 can associate with a v or a IIb subunits to function as a vitronectin or fibrinogen receptor, respectively. a v b 3 is found on endothelial cells (Cheresh et al, 1989) . Interestingly, the authors demonstrated that this antibody could disturb endothelial cell adhesion onto vitronectin, trigger endothelial cell apoptosis and interfere with endothelial tube formation. Moreover, it has been demonstrated that anti-endothelial a v b 3 antibodies are a major cause of intracranial haemorrhage in fetal/neonatal alloimmune thrombocytopenia cases . Although further research on the clinical consequences of this type of immunization is required, its identification might have potential in the diagnostic prediction of intracranial haemorrhage development in immunized GT pregnant patients.
Therapeutic approach in GT patients with anti-a IIb b 3 antibodies

Platelet transfusions
Currently, platelet transfusions are considered as the first-line therapy for severe bleeding in GT patients. However, in case of anti-a IIb b 3 immunization, the active site of the receptor of transfused platelets can be blocked and/or platelets be rapidly removed from the circulation, rendering patients refractory to further transfusions.
In the international GT registry (GTR), data were collected from 218 patients (45 sites in 15 countries from four continents). As such, the GTR is the largest observational study reporting on GT patients. In total, the analysis was performed using data from 829 admissions for non-surgical bleeding and 206 surgical admissions Poon et al, 2015) .
Investigators reported that for the non-surgical bleeds that occurred in patients with a history of antiplatelet antibodies (without distinction between anti-a IIb b 3 and anti-HLA antibodies) AE platelet refractoriness, platelet transfusions was the mostly used treatment (53%) , although the type of platelet concentrates used was not stated. This treatment was, not surprisingly, less effective in these patients compared to the group without antibodies (65% vs. 85%).
In contrast, recombinant activated factor VII (rFVIIa) AE antifibrinolytics (AF) was mostly used in surgical admissions of patients with a history of antiplatelet antibodies AE platelet refractoriness . Platelet transfusions AE AF were considered to be effective in 71% of cases in which they were used (the type of platelet concentrates used was not stated).
Finally, some of the procedures in the immunized patients group had a successful outcome using platelet transfusions. Explanations might be (i) due to the disappearance of antibodies at the time of transfusion; (ii) that these antibodies are not neutralizing (iii); or that they could be absorbed by the transfused platelets. These observations suggest that platelet transfusions may be attempted in such patients when other agents are ineffective or not available.
Platelet transfusions of GT patients with anti-a IIb b 3 antibodies should be performed in specialized centres where blood products are easily accessible. The two types of available platelet products are whole blood-derived or apheresis platelet concentrates. After collection, blood donations may undergo a process whereby white blood cells are removed. Platelet concentrates should be kept at room temperature and ideally be used within 2 days following blood donation. Unfortunately, no clinical trials have previously investigated whether the type of transfusion (single donor apheresis versus pooled platelets) could constitute a risk factor of antia IIb b 3 immunization. There is no preference regarding the choice of platelet concentrates unless the patient has developed specific anti-human platelet antigen (HPA) antibodies, where only apharesis platelet concentrates allow the choice of a phenotypically compatible donor. ABO compatibility is preferred as it improves the platelet yield. In France, the National Security Agency of Medicines and Health Products recommends that platelets should be transfused at a dose of 0Á5-0Á7 9 10 11 per 7 kg of body weight in adults. Lastly, platelet transfusions should be continued until the bleeding risk is under control. Post-transfusion purpura (PTP) is a rare form of alloimmune thrombocytopenia where the transfused platelets, which bear a foreign antigen, and the patient's own platelets, which lack it, are both eliminated (Loren & Abrams, 2004) . HPA-1 is a polymorphic epitope near the amino terminus of b 3 with two isoforms, HPA-1a and HPA-1b. Most patients who develop PTP are homozygous for HPA-1b, although other platelet antigens have been implicated. To our knowledge, this complication has never been reported in GT patients. This is not surprising, as about 75% of GT patients do not express the complex at their platelet surface (Kunicki & Aster, 1978; van Leeuwen et al, 1981) . However, this process could be possible in rare GT patients with residual integrin expression, bearing (for instance) the HPA-1b platelet antigen in the homozygous state.
Detection of transfused platelets
The haemostatic efficacy of platelet transfusions is often assessed on the basis of clinical or laboratory data (estimation of blood loss, monitoring of haemoglobin levels, etc.). As patients suffering from GT have normal platelet counts, estimation of platelet recovery after transfusion is therefore not possible. Nevertheless, multiple case studies reported that flow cytometry could be used to estimate the survival of transfused platelets (Nurden et al, 2002; Male et al, 2006; Cesar & Vecino, 2009; Kashiwagi et al, 2011) . When there is no significant binding of anti-CD61 (b 3 ) or anti-CD41 (a IIb ) monoclonal antibodies to the patient's platelets, quantification of a IIb b 3 by flow cytometry can be used to monitor the survival of transfused platelets. It is also possible to assess the function of transfused platelets by measuring PAC-1 (an antibody that recognizes the active form of the integrin) or fibrinogen binding after platelet activation (Kashiwagi et al, 2011) . However, some laboratories do not perform flow cytometry and other platelet function tests to assess platelet transfusion efficacy in GT have also been reported.
Indeed, Male et al (2006) were able to estimate the contribution of transfused platelets to clot formation by thromboelastography. A measure of platelet-dependent clot strength was zero before transfusion, but significantly increased after platelet concentrates administration (Male et al, 2006) . Cesar and Vecino (2009) first described the function of transfused platelets by aggregation assays. A GT patient was given three platelet concentrates and one hour after transfusion, platelet aggregation tests detected a minor, but measurable, response to collagen, while no aggregation was found to other agonists (Cesar & Vecino, 2009) test the hypothesis that GT platelets interfere with the function of normal transfused platelets, in vitro studies were performed using different proportions of citrated blood from a GT patient mixed with blood from a normal control donor. A mixture containing 75% of normal control blood was required to correct PFA-100 closure times of the GT patient.
Antibodie removal
Antibody removal therapy has been successfully used in immunized GT patients. Vivier et al (1989) reported a caesarean section scheduled after therapeutic plasmapheresis. The plasma exchange rendered platelet transfusions possible as anti-a IIb b 3 antibodies were reduced to trace levels and the caesarean section was therefore safely performed (Vivier et al, 1989) . In a 31-year-old Japanese pregnant woman with antibodies against a IIb b 3 , antibody removal therapy was carried out three times. After the rate of antiplatelet antibodies decreased, platelets were transfused and delivery was successfully induced despite atonic haemorrhage (Ito et al, 1991) . Martin et al (2002) used immunoadsorption on protein A Sepharose in three patients on five different occasions. Immunoadsorption was well tolerated without deleterious side-effects. It induced a dramatic decrease of anti-a IIb b 3 antibody levels, and this approach followed by platelet transfusion made it possible to control two life-threatening haemorrhages, and allowed two surgical procedures and one bone marrow transplantation to be performed safely (Martin et al, 2002) .
Recombinant activated factor VII (rFVIIa)
The first successful use of rFVIIa was reported in the management of intractable epistaxis in a GT 2-year old child (Tengborn & Petruson, 1996; Rajpurkar et al, 2014) . Only a few years later, its use in a patient with anti-a IIb b 3 antibodies and refractoriness to platelet transfusions was described: a one-year-old female successfully treated for severe gastrointestinal bleeds with a standard dose of approximately 90 lg/ kg every 2 h until bleeding stopped (Poon et al, 1999) . While the mechanism of action of rFVIIa in GT is not currently fully understood, it is thought that rFVIIa increases thrombin generation by factor X activation on the platelet surface (Di Minno, 2015) . Tissue factor-independent rFVIIa-mediated thrombin formation can restore defective adhesion of a IIb b 3 -deficient platelets to extra-cellular membrane (Lisman et al, 2003) and may induce a IIb b 3 -independent platelet aggregation of washed platelets from GT patients (Lisman et al, 2004) . rFVIIa also interacts with the glycoprotein (GP) Ib-IX-V complex, and this interaction enhances tissue factorindependent thrombin generation mediated by rFVIIa on the activated platelet surface (Weeterings et al, 2008) .
Prior to the approval of rFVIIa for GT patients with antiplatelet antibodies, a larger international survey of its efficacy and safety was conducted in 59 patients (Poon et al, 2004) . The results of the survey showed that efficacy was achieved in 29/31 (94%) evaluable procedures, and 77/103 (75%) evaluable bleeding episodes, whereas no significant difference in efficacy was observed between patients with and without platelet antibodies. Data from this survey led to the suggestion of an optimal rFVIIa regimen (rFVIIa ≥80 lg/kg given at ≤2Á5-h intervals for three or more doses) for the treatment of moderate/severe bleeding episodes, but on the other hand, results were not statistically significant concerning minor bleeds.
In the large international GTR, investigators reported that for non-surgical bleeds that occurred in patients with a history of antiplatelet antibodies (without distinction between anti-a IIb b 3 and anti-HLA antibodies) AE platelet refractoriness, rFVIIa (either alone or with AF) was considered effective in 76% of cases, whereas it was effective in 91% of the group without antibodies . Moreover, the number of rFVIIa doses and overall duration of treatment were greater in patients with a history of antiplatelet antibodies AE refractoriness to platelets than in subjects without such a history.
For surgical procedures, the use of rFVIIa AE AF was considered effective in 88% and 100%, respectively for the antibodies AE refractoriness group and subjects without such a history. Concerning minor procedures, median dose and dosage interval of rFVIIa was very similar for the different patient groups. However, the median cumulative rFVIIa dose range and duration of treatment used were found to be higher in the group with a history of antiplatelet antibodies AE refractoriness.
Due to the rarity of the disease, no clinical trials of rFVIIa have been performed by Novo Nordisk A/S in this setting. Therefore, data on thrombo-embolic events are available only from post-marketing sources. Neufeld et al reported (over the review period: data up to 31 December 2013), 12 cases of thrombo-embolic events in eight patients (Neufeld et al, 2015) . A fatal outcome occurred in two of them; of two further patients, one recovered completely and the other recovered with sequelae.
Overall, these results confirm that rFVIIa is safe in patients with anti-platelet antibodies AE refractoriness, though surprisingly, the effective rate was slightly lower compared to patients without antibodies and the cumulative doses needed were higher; this was probably due to more serious bleeding episodes. Data from the GTR also indicated that rFVIIa is frequently used off-label for bleeding and surgical procedures, irrespective of platelet antibodies and/or platelet refractoriness. However, rFVIIa has been associated with development of venous or arterial thrombosis during its use and it should be prescribed with caution in patients with thrombosis risk factors. Among patients included in the GTR study, a nonfatal thromboembolic event has been reported in an adult woman treated with rFVIIa + platelets + AF.
Bone marrow transplantation
In cases where severe bleeding is recurrent and refractory to platelet transfusions due to anti-a IIb b 3 antibodies, allogenic bone marrow transplantation (BMT) may be the only remaining therapeutic option and it has been successfully reported in several GT families.
Only five patients with anti-a IIb b 3 antibodies present before BMT have been described, most of them having type I GT (Bellucci et al, 1985 (Bellucci et al, , 2000 Flood et al, 2005; Ishaqi et al, 2009; Kitko et al, 2011; Wiegering et al, 2013) . Age at transplantation ranged from 4 to 16 years. One patient was transplanted from an unrelated donor and four from matched sibling donors. All patients achieved 100% donor platelets by flow cytometry post-BMT. Bleeding symptoms clinically resolved, but three patients developed chronic graft-versushost disease.
Finally, pre-existing anti-a IIb b 3 antibodies do not automatically predict platelet non-engraftment after transplantation. Nonetheless, despite the favourable outcome and long-term cure of the five reported cases, indication for allogeneic BMT should only be proposed after careful assessment of risk-benefit.
Pregnancy
Given the previously described related-risk factors, some recommendations can be put forward. The risks of a pregnancy should be discussed between the affected couple and a multidisciplinary team. Consequences of fetal placental transfer of maternal antibodies against a IIb b 3 need to be given (fetal bleeding and/or thrombocytopenia). The pregnancy should be closely monitored, particularly in women with high risk of immunization (rising maternal antibodies, fetal thrombocytopenia or intracranial haemorrhage during previous pregnancies). Platelet-specific antibodies should be tested at the start of pregnancy and at a regular intervals (titre and specificity of anti-a IIb b 3 antibodies). Maternal intravenous immunoglobulin, oral corticosteroids, plasma exchange or immunoabsorption may reduce the titre of antibodies (see above). Newborns at risk of thrombocytopenia should be screened on cord blood platelet count and evaluation of intracranial haemorrhage should be determined using cranial ultrasound. Finally, as maternal anti-a IIb b 3 antibodies are associated with fetal/neonatal risks, the development of immunization in non-pregnant women should be avoided as much as possible. 
Conclusion
While the epidemiology of neutralizing antibodies (inhibitors) is well known in patients with haemophilia A (Hay et al, 2011) , it has been relatively poorly studied in GT patients. Despite some reports, there is no consensus pertaining to their frequency, long-term evolution in the circulation, or formation in relation to the nature of the genetic defect (ITGA2B or ITGB3 genes). The reasons that only 20-30% of GT patients develop anti-a IIb b 3 antibodies remain obscure, but observations indicate that genetic factors might be of major importance. Stratification of patients by risk for antibody development is of clinical significance to individualize and optimize treatment. One approach is to avoid, when possible, platelet transfusions in higher risk patients, given that antibodies will not be formed without this exposure. Although platelet transfusions remain the choice for stopping haemorrhage, where bleeding is moderate, rFVIIa appears to represent a good alternative therapeutic option. It could be particularly so for patients with high genetic risk factors (Fig 1) . For instance, rFVIIa could be used "off label" for young females without anti-a IIb b 3 antibodies to reduce the risk of neonatal thrombocytopenia in case of pregnancy. However, the "off-label" use of rFVIIa is controversial, as success with rFVIIa is subjectively defined in retrospective case series. In some situations, such as gastrointestinal bleeding, the use of antifibrinolytic therapy (e.g. tranexamic acid) may be more appropriate and carry a much lower risk of thrombosis.
Clinical research on antibodies towards a IIb b 3 is challenged by the fact that this is an infrequent event occurring in a rare disease. In addition, the limited amount of published data renders interpretations more difficult as studies are often retrospective and insufficiently documented. Future work should focus on improving assays that detect and quantify inhibitory anti-a IIb b 3 antibodies, examining the pathophysiology of antibodies formation using contemporary immunological tools, and investigating new treatment modalities. Registries, as information sources, to supplement available evidence regarding predictors of anti-a IIb b 3 antibodies development are still needed.
